40. 高安動脈炎 Disease details / Clinical trials / Drug dev / DR info

Adalimumab
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
      2020   Phase 4   NCT04300686   China
Adalimumab injection
   Chinese SLE Treatment And Research Group
      2022   Phase 4   NCT05151848   China
ANTI-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Autologous peripheral blood stem cell transplantation
   Fairview University Medical Center
      2000   -   NCT00006055   United States
AZA
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
Baricitinib 4 MG
   Liu Tian
      2023   Phase 2   NCT06662721   China
Bosentan
   University of Edinburgh
      2025   Phase 2   NCT06887062   United Kingdom
Clopidogrel
   Jose Carlos Nicolau
      2024   -   NCT06807788   Brazil
Computed tomography
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States
CYC
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
Cyclophosphamide
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Fluorine F 18 clofarabine
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States
Genetic sequencing
   China National Center for Cardiovascular Diseases
      2017   -   NCT03199183   China
Glucocorticoids
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
Glucorticoid taper regimen
   Janssen Pharmaceutical K.K.
      2021   Phase 3   NCT04882072   Japan
   Nishikawa Kazuko
      2021   Phase 3   JPRN-jRCT2061210007   -
Infliximab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 3   EUCTR2018-003753-13-FR   France
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT04564001   -
   Cambridge University Hospitals NHS Foundation Trust
      2021   Phase 2   NCT05168475   United Kingdom
   Ospedale San Raffaele
      2017   -   NCT03192878   Italy
Laboratory biomarker analysis
   China National Center for Cardiovascular Diseases
      2017   -   NCT03199183   China
Leflunomide
   Jiang lindi
      2016   -   NCT02981979   China
   Shanghai Zhongshan Hospital
      2016   -   NCT03893136   China
Methotrexate
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
      2021   Phase 4   NCT05102448   China
Methotrexate tablets
   Shanghai Zhongshan Hospital
      2020   Phase 4   NCT04299971   China
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006055   United States
MMF
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
MTX
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
Naltrexone hydrochloride
   University of Pennsylvania
      2019   Phase 2   NCT03482479   Canada;United States
PET-CT
   China National Center for Cardiovascular Diseases
      2017   -   NCT03199183   China
Positron emission tomography
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States
Prednisolone
   AbbVie
      2020   Phase 3   NCT04161898   Argentina;Brazil;China;Japan;Korea, Republic of;Turkey
Prednisone
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
Prednisone acetate tablets
   Jiang lindi
      2016   -   NCT02981979   China
Prednisone, cyclophosphamide
   Chinese Academy of Medical Sciences, Fuwai Hospital
      2018   Phase 2/Phase 3   NCT03550781   -
Rituximab
   Cambridge University Hospitals NHS Foundation Trust
      2021   Phase 2   NCT05168475   United Kingdom
Roactemra 20MG/ML
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 3   EUCTR2018-003753-13-FR   France
Tocilizumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 3   EUCTR2018-003753-13-FR   France
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT04564001   -
      2014   Phase 3   NCT02101333   France
   Cambridge University Hospitals NHS Foundation Trust
      2021   Phase 2   NCT05168475   United Kingdom
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 3   JPRN-jRCT2080222565   Japan
   Department of Cardiovascular Medicine Graduate School of Medicine Osaka University
      2012   -   JPRN-UMIN000007845   Japan
   Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity
      2012   -   JPRN-UMIN000008812   Japan
   Osaka University
      2017   -   JPRN-UMIN000025940   Japan
   Osaka Unversity
      2014   -   JPRN-UMIN000025943   Japan
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
      2020   Phase 4   NCT04300686   China
      2016   -   NCT03893136   China
Tofacitinib
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
      2021   Phase 4   NCT05102448   China
Tofacitinib 5 MG
   Chinese SLE Treatment And Research Group
      2022   Phase 4   NCT05151848   China
Tofacitinib tablet
   Shanghai Zhongshan Hospital
      2020   Phase 4   NCT04299971   China
Upadacitinib
   AbbVie
      2020   Phase 3   NCT04161898   Argentina;Brazil;China;Japan;Korea, Republic of;Turkey
Ustekinumab
   Janssen Pharmaceutical K.K.
      2021   Phase 3   NCT04882072   Japan
   Nishikawa Kazuko
      2021   Phase 3   JPRN-jRCT2061210007   -
Yellow fever vaccine
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil